Farmak International Launches Propofol in the UK Market

Farmak International has officially launched Propofol in the United Kingdom, following MHRA marketing authorisation earlier this year. The product has now entered active distribution, marking the start of supply to one of Europe’s most strictly regulated hospital markets.

Propofol is a short-acting intravenous anaesthetic widely used for the induction and maintenance of general anaesthesia and sedation in intensive care. Farmak International’s formulation is manufactured at GMP-certified sterile production sites, reflecting the company’s commitment to dependable quality in critical care.

The UK product range includes:

  • Propofol 10 mg/mL emulsion in vials

  • Propofol 10 mg/mL emulsion in ampoules

  • Propofol 20 mg/mL emulsion in vials

All forms are classified as prescription-only medicines (POM) and are designed to meet diverse clinical needs. The availability of both 10 mg/mL and 20 mg/mL concentrations provides dosing flexibility across anaesthesia and intensive care settings. The higher concentration option allows for reduced infusion volumes, which may be advantageous for fluid-restricted patients and long-duration procedures, while supporting hospital efficiency in storage and administration.

This addition strengthens Farmak International’s UK hospital portfolio, which also includes ICU therapies, anaesthetics, emergency-use medicines, and contrast agents.

Explore the full UK portfolio.

Partner with Us

Farmak International welcomes new distribution and hospital procurement partners across the UK and Ireland.
For partnership opportunities, contact: bd@farmak.uk

This announcement contains information on a product that is intended for healthcare professionals only. Propofol Emulsion for Injection or Infusion is a prescription-only medicine and should be administered by qualified medical personnel in appropriate clinical settings. Always refer to the full Summary of Product Characteristics (SmPC) and national prescribing guidelines.